文献速递造血干细胞移植与细胞治疗

异基因造血细胞移植后激素依赖性急性GVHD:危险因素与临床结局

Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在1143例连续成人和儿童异基因造血细胞移植受者中,依据一线糖皮质激素治疗反应将急性GVHD分为激素敏感(SS)、激素依赖(SD)和激素抵抗(SR)三组。385例(34%)发生aGVHD,其中SS占10%、SD占9%、SR占14%。与SS相比,SD唯一显著相关因素为年龄较大(18-60岁 vs <18岁,OR 3.9,95%CI 1.4-11.3);SR与无关供者(OR 3.0,95%CI 1.2-7.4)和Minnesota高危aGVHD(OR 2.4,95%CI 1.3-4.6)相关。SR独立关联更高的2年总体死亡率(HR 1.8,95%CI 1.2-2.8)和非复发死亡率(HR 2.1,95%CI 1.2-3.9)。SS与SD组总体生存和非复发死亡率相似,SD组慢性GVHD累积发生率最高(46%),其次SR(41%)和SS(29%)。

要点

  • 激素依赖性aGVHD与激素敏感型预后相似,均明显优于激素抵抗型。
  • 年龄较大(18-60岁 vs <18岁)与激素依赖性aGVHD显著相关。
  • 激素抵抗型aGVHD独立关联更高的2年总体死亡率和非复发死亡率。

核心结论

  • 激素依赖性和激素敏感性aGVHD预后相似,均显著优于激素抵抗性aGVHD。
  • 激素抵抗性aGVHD独立关联更高的2年总体死亡率和非复发死亡率。

研究设计与样本

  • 研究纳入1143例连续成人和儿童异基因造血细胞移植受者,依据一线糖皮质激素治疗反应分组。
  • 385例(34%)发生aGVHD,其中激素敏感占10%、激素依赖占9%、激素抵抗占14%。

主要发现

  • 与激素敏感相比,激素依赖唯一显著相关因素为年龄较大(18-60岁 vs <18岁,OR 3.9,95%CI 1.4-11.3)。
  • 与激素敏感相比,激素抵抗显著相关因素为无关供者(OR 3.0,95%CI 1.2-7.4)和Minnesota高危aGVHD(OR 2.4,95%CI 1.3-4.6)。
  • 激素抵抗独立关联更高的2年总体死亡率(HR 1.8,95%CI 1.2-2.8)和非复发死亡率(HR 2.1,95%CI 1.2-3.9)。
  • 激素敏感和激素依赖组总体生存和非复发死亡率相似。
  • 慢性GVHD累积发生率在激素依赖组最高(46%),其次激素抵抗(41%)和激素敏感(29%)。

临床怎么用

  • 临床可依据一线糖皮质激素治疗反应将aGVHD分为激素敏感、激素依赖和激素抵抗,以评估预后。
  • 激素依赖性aGVHD患者预后与激素敏感相似,但慢性GVHD累积发生率最高,需加强监测。
  • 激素抵抗性aGVHD患者死亡风险显著升高,应尽早识别并考虑强化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) has various risk factors and outcomes. We defined distinct aGVHD treatment response groups based on response to first-line corticosteroids: steroid sensitive (SS), steroid resistant (SR), and the rarely studied steroid dependent (SD) aGVHD. In 1143 consecutive adult and pediatric allogeneic hematopoietic cell transplant recipients, 385 (34%) developed aGVHD, with 10% having SS aGVHD, 9% SD aGVHD, and 14% SR aGVHD. The only factor significantly associated with SD in comparison with SS was older age (odds ratio [OR], 3.9; 95% confidence interval [CI], 1.4-11.3, when comparing 18- to 60-year-olds with <18-year-olds). Factors significantly associated with SR in comparison with SS were unrelated donor (OR, 3.0; 95% CI, 1.2-7.4) and Minnesota high-risk aGVHD (OR, 2.4; 95% CI, 1.3-4.6). SR aGVHD was independently associated with higher risk for 2-year overall mortality (hazards ratio [HR], 1.8; 95% CI, 1.2-2.8) and nonrelapse mortality (NRM; HR, 2.1; 95% CI, 1.2-3.9). SS and SD GVHD groups had similar overall survival and NRM. The cumulative incidence of chronic GVHD was highest in the SD group, followed by the SR and SS groups (46%, 41%, and 29%, respectively). SD and SS GVHD had similar prognoses, both markedly better than those of the SR groups.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. El Jurdi N, Rayes A, MacMillan ML, et al. Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. Blood Adv. 2021. PMID: 33656537. doi:10.1182/bloodadvances.2020003937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。